Visiongain, a independent media company, issued the following news:. Visiongain has launched a new pharma report Top Pre-Filled Injection Device Manufacturers 2018-2028: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services. Pre-filled syringes provide users with a number of advant
Directly employed 311,226 Californians with an average wage of $119,000 Generated $178 billion in revenue Projected to attract $7.6 billion in venture capital and $3.9 billion in NIH investment Over 1,300 new medicines in clinical trials. SAN FRANCISCO& SACRAMENTO, Calif.& SAN DIEGO& WASHINGTON California Life Sciences Association, the trade as
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal second quarter ended September 30, 2018.
Acquist Therapeutics, Inc., a biopharmaceutical company committed to bettering the lives of people with inflammatory diseases, presented results for its investigational drugs for patients with NASH. Raymond P. Warrell, Jr., at The Liver Meeting , held by the American Association for the Study of Liver Diseases in San Francisco. Dr. Warrell comm
Aggressive Lymphoma Results from Prospective Clinical Trials: New Agents Date and Time: Sunday, December 2, 2018; 12:15 p.m. PT Location: Marriott Marquis San Diego Marina, Pacific Ballroom 20 Presenter: John Radford, MD, FRCP, Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided a business update for the third quarter 2018, as well as recent activities, and has filed its Current Report on Form 10- Q for the quarter ended September 30, 2018, which is available at www.sec.gov.
The discussion should be read in conjunction with our unaudited financial statements and the notes presented herein and the audited financial statements and the other information set forth in the Prospectus that forms a part of our Registration Statement on Form S-1, which was filed with the Securities and Exchange Commission pursuant to Rule 424 o
MENLO PARK- Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in the upcoming 30th Annual Piper Jaffray Healthcare Conference in New York, NY. Adverum's management is scheduled to present on Tuesday, November 27, 20
-Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, is pleased to announce the successful presentation of a live webinar demonstrating the Zepto Precision Pulse Capsulotomy devices ability to address challenging capsulotomy cases during cataract surgery.
Agency: " Food and Drug Administration, HHS." SUMMARY: The Food and Drug Administration is announcing that a proposed collection of information has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food an
SAN DIEGO- Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been dosed in the Company's Phase 2 clinical program to evaluate the efficacy and safety of APX001 in the treatment of infections caused by Candida. 'Initiating our Phase 2 program for APX001...
Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been dosed in the Company`s Phase 2 clinical program to evaluate the efficacy and safety of APX001 in the treatment of infections caused by Candida. "Initiating our Phase 2 program for APX001 represents a
LONDON, GREATER LONDON, UK, November 14, 2018/ EINPresswire.com/ In North America, which accounts for over 30% of the global market, sales of drugs to treat or prevent infectious diseases are falling at 0.1% year on year, as Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021 from The Business Research Company shows. Sales in
Aravive, Inc., a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers. As previously announced, the trial met the safety and tolerability endpoints for the trial and demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, a k
ASIT biotech, a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, today announced that it has finalized the industrialization process for the manufacture of clinical batches of its pnt-ASIT+ product candidate. Mohamed Shamji and his team on the blood cells of allergic patient
Attenua, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced that the first patient has been treated in a Phase 2 clinical trial in chronic cough with bradanicline, its lead compound. "Within just six months of our initial Series A funding, Attenua has successfully filed an Inves
"We're happy to establish Grnenthal's commercial footprint in the largest pharma market in the world," says Douglas Stefanelli, President of Averitas Pharma. To support the Qutenza commercialization, Averitas Pharma expects to add new positions in New Jersey and across the country. Qutenza has a broad neuropathic pain label in Europe and Av
Axsome Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced the completion of patient enrollment in the ASCEND study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder. ASCEND is evaluating the effect of AXS-05 as compa
Basilea Pharmaceutica AG/ Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium. Processed and transmitted by West Corporation. *Late-breaking abstracts on increased cure rates and synergistic effects of combinations with eribulin and gemcitabine in solid tumor models* Enhanced survival in a brain.
Baxter International Inc., a leading global medical products company, is presenting four health economics and outcomes research analyses this week at the International Society for Pharmacoeconomics and Outcomes Research Europe 2018 meeting. Malnutrition occurs in roughly 40 to 60 percent of cancer patients worldwide1, 2 and is a frequent complicati
The Global Coalition for Adaptive Research and Bayer announced today that Bayer s regorafenib will be the first drug to enter GBM AGILE. GBM AGILE is a revolutionary patient-centered adaptive platform trial that will evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma the deadliest form of brain canc
CAMBRIDGE, England& BOSTON Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced that it has been recognized at the 2018 World ADC Awards, held during the World ADC Conference in San Diego, Calif., as Best New Drug Developer. Earlier this
Biologic injectors are the injecting devices used to deliver drugs and other substances for biological purposes. Biological products such as drugs, growth hormones, antibodies and other complex biological molecules are administered into the body of an organism through biologic injectors. Biologic injectors are basically used for the treatment of...
Owing to the changing perception towards biosimilars and favorable guidelines laid down by the European Medicines Agency, the biosimilar market in Europe has witnessed a robust growth over the past several years. IMARC Group's latest report, entitled "Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced positive results from a Phase 1 b study evaluating intravenously administered dexmedetomidine for acute treatment of agitation...